PRECIGEN, INC. Other Receivables, Net, Current
PRECIGEN, INC. (PGEN) had Other Receivables, Net, Current of $178.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Nontrade Receivables
us-gaap:OtherReceivablesNetCurrent · last filed 2026-08-04
- 2026-06-30: Other Receivables, Net, Current $178.00K.
- 2026-03-31: Other Receivables, Net, Current $302.00K.
- 2025-12-31: Other Receivables, Net, Current $446.00K.
- 2025-09-30: Other Receivables, Net, Current $520.00K.
| Period end | Other Receivables, Net, Current |
|---|---|
| 2026-06-30 | $178.00K 10-Q · filed 2026-08-04 |
| 2026-03-31 | $302.00K 10-Q · filed 2026-05-13 |
| 2025-12-31 | $446.00K 10-Q · filed 2026-08-04 |
| 2025-09-30 | $520.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $244.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $313.00K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $237.00K 10-K · filed 2026-03-25 |
| 2024-09-30 | $250.00K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $505.00K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $290.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $673.00K 10-K · filed 2025-03-19 |
| 2023-09-30 | $13.12M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $13.05M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $13.75M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $12.83M 10-K · filed 2024-03-19 |
| 2022-09-30 | $1.26M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $546.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $543.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | $566.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $848.00K 10-Q · filed 2021-11-08 |
| 2021-06-30 | $633.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $555.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | $232.00K 10-K · filed 2022-03-01 |
| 2019-12-31 | $2.03M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |